Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy 2016 | The price of new innovation for the treatment of multiple myeloma

Eric Low • 12 Apr 2016
COMy 2016
Multiple Myeloma

Eric Low, Chief Executive of Myeloma UK, discusses recent advances in the development of new drugs for the treatment of patients with multiple myeloma and emphasises the importance of determining the cost effectiveness of new therapeutic approaches to ensure patient access.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

More from Eric Low

Why global collaborations are key in multiple myeloma
2:50
Why global collaborations are key in multiple myeloma
Eric Low • 28 Apr 2016
Improving strategies for executing successful clinical trials in multiple myeloma
3:28
Improving strategies for executing successful clinical trials in multiple myeloma
Eric Low • 8 Jun 2016
Myeloma UK as a driver of collaboration between industry and academia
1:41
Myeloma UK as a driver of collaboration between industry and academia
Eric Low • 7 Oct 2016
The rationale behind the Myeloma UK Clinical Trial Network
3:05
The rationale behind the Myeloma UK Clinical Trial Network
Eric Low • 7 Oct 2016

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Eric Low • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Eric Low • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Eric Low • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Eric Low • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals